HOUSTON, Texas – Nov. 19, 2025 – EMPIRI Inc., the pioneering company behind E-slice, today received a $2.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This grant will support the validation of E-slice as clinical diagnostic for immunotherapies in breast, renal, and lung cancers. E-slice is an ex vivo assay that empirically measures a tumor’s response to therapeutics within days, enabling oncologists to select the best therapy for each patie

We are incredibly honored to be named one of just 31 companies in the prestigious BioTools Innovator 2025 cohort, selected from over 420 applicants worldwide!  This highly competitive program, run by the premier global accelerator for life science tools and diagnostics, recognizes the most innovative early-stage companies poised to transform healthcare.  At EMPIRI, our E-Slice platform is revolutionizing functional precision diagnostics by enabling real-time, ex vivo testing

Associate Professor in the Department of Neorology, Houston Methodist, Weill Cornell Medical College Inaugural Chair of Neurodegenerative Disease Research, Houston MethodistCofounder, biotech company EMPIRI Kyuson Yun, Ph.D. is an Associate Professor in the Department of Neurology at the Houston Methodist and Weill Cornell Medical College. She is also the inaugural Houston Methodist Chair of Neurodegenerative Disease Research, and a cofounder of a biotech company EMPIRI. She

Join us for a presentation by Dr. Kyuson Yun titled "E-Slices with Intact TME for Empirical Response Measurements for Immunotherapies and Other Drugs from Human Tumors" at the 6th Annual GCC Innovative Drug Discovery and Development Conference , May 6-7, 2025 at the BioScience Research Collaborative, 6500 Main St., Houston, TX